

# Plasma radio–metabolite analysis of PET tracers for dynamic PET imaging: TLC and autoradiography

**Fiona Li**

The University of Western Ontario <https://orcid.org/0000-0002-2423-6953>

**Justin W Hicks**

Lawson Health Research Institute

**Lihai Yu**

Lawson Health Research Institute

**Lise Desjardin**

Lawson Health Research Institute

**Laura Morrison**

Lawson Health Research Institute

**Jennifer Hadway**

Lawson Health Research Institute

**Ting-Yim Lee** (✉ [tlee@robarts.ca](mailto:tlee@robarts.ca))

<https://orcid.org/0000-0001-7605-9752>

---

## Original research

**Keywords:** [18F]FEPPA, [18F]FAZA, Radio-metabolite Correction, Thin Layer Chromatography (TLC), Dynamic PET, Autoradiography

**Posted Date:** September 11th, 2020

**DOI:** <https://doi.org/10.21203/rs.3.rs-35592/v3>

**License:**  This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

---

**Version of Record:** A version of this preprint was published on November 23rd, 2020. See the published version at <https://doi.org/10.1186/s13550-020-00705-2>.

**Plasma radio–metabolite analysis of PET tracers for dynamic PET imaging: TLC and autoradiography**

<sup>1,2,3</sup>Fiona Li, <sup>1,2</sup>Justin W. Hicks, <sup>2</sup>Lihai Yu, <sup>2</sup>Lise Desjardin, <sup>2</sup>Laura Morrison, <sup>2,3</sup>Jennifer Hadway and <sup>1,2,3</sup>Ting-Yim Lee

<sup>1</sup>Department of Medical Biophysics, The University of Western University, London, Ontario, Canada

<sup>2</sup>Lawson Health Research Institute, London, Ontario, Canada

<sup>3</sup>Robarts Research Institute, London, Ontario, Canada

**EMAIL ADDRESSES:**

Fiona Li: [fli222@uwo.ca](mailto:fli222@uwo.ca)

Justin W Hicks: [jhicks@lawsonimaging.ca](mailto:jhicks@lawsonimaging.ca)

Lihai Yu: [lihai\\_yu@hotmail.com](mailto:lihai_yu@hotmail.com)

Lise Desjardin: [ldesjard@lawsonimaging.ca](mailto:ldesjard@lawsonimaging.ca)

Laura Morrison: [lmorrison@lawsonimaging.ca](mailto:lmorrison@lawsonimaging.ca)

Ting-Yim Lee: [tlee@imaging.robarts.ca](mailto:tlee@imaging.robarts.ca)

**CORRESPONDING AUTHOR**

Ting-Yim Lee, PhD, FCCPM, FCOMP

Director of Functional CT Imaging Lab

Lawson Health Research Institute

And Robarts Research Institute

Professor, Medical Imaging, Medical Biophysics, Oncology

The University of Western Ontario

1151 Richmond Street North

London, Ontario, N6A 3K,

Canada

## Background

In molecular imaging with dynamic PET, the binding and dissociation of a targeted tracer is characterized by kinetics modeling which requires the arterial concentration of the tracer to be measured accurately. Once in the body the radiolabeled parent tracer may be subjected to hydrolysis, demethylation/dealkylation and other biochemical processes, resulting in the production and accumulation of different metabolites in blood which can be labeled with the same PET radionuclide as the parent. Since these radio-metabolites cannot be distinguished by PET scanning from the parent tracer, their contribution to the arterial concentration curve has to be removed for the accurate estimation of kinetic parameters from kinetic analysis of dynamic PET. High performance liquid chromatography has been used to separate and measure radio-metabolites in blood plasma, however, the method is labor intensive and remains a challenge to implement for each individual patient. The purpose of this study is to develop an alternate technique based on thin layer chromatography (TLC) and a sensitive commercial autoradiography system (Beaver, Ai4R, Nantes, France) to measure radio-metabolites in blood plasma of two targeted tracers – [ $^{18}\text{F}$ ]FAZA and [ $^{18}\text{F}$ ]FEPPA, for imaging hypoxia and inflammation respectively.

## Results

Radioactivity as low as 17Bq in 2 $\mu\text{L}$  of pig's plasma can be detected on the TLC plate using autoradiography. Peaks corresponding to the parent tracer and radio-metabolites could be distinguished in the line profile through each sample ( $n=8$ ) in the autoradiographic image. Significant inter-subject and intra-subject variability in radio-metabolites production could be observed with both tracers. For [ $^{18}\text{F}$ ]FEPPA, 50% of plasma activity was from radio-metabolites as early as 5 min post injection while for [ $^{18}\text{F}$ ]FAZA, significant metabolites did not appear until 50 min post. Simulation study investigating the effect of radio-metabolite in the estimation of kinetic parameters indicated that 32-400% parameter error can result without radio-metabolites correction.

## Conclusion

TLC coupled with autoradiography is a good alternative to high performance liquid chromatography for radio-metabolite correction. The advantages of requiring only small blood samples ( $\sim 100 \mu\text{L}$ ) and of analyzing multiple samples simultaneously, make the method suitable for individual dynamic PET studies.

**Keywords:** [ $^{18}\text{F}$ ]FEPPA, [ $^{18}\text{F}$ ]FAZA, Radio-metabolite Correction, Thin Layer Chromatography (TLC), Dynamic PET, Autoradiography

## 1. Background

To derive molecular/metabolic information from dynamic positron emission tomography (PET), a kinetic analysis of the radiolabeled tracer is required. Obtaining the time concentration curve of the radiotracer in blood plasma, the arterial input function (AIF), is crucial to accurately portray the pathophysiology. One frequently used method is to sample arterial blood serially and use a radiation detector to measure the activity in the blood samples. The detector only detects the annihilation photons from the decaying positron-emitting isotope and cannot distinguish whether the radionuclide remains attached to the parent tracer or its metabolites (1). AIF can also be image derived obtained by measuring the activity in an arterial region in dynamic PET. Regardless of the method, measuring the activity in blood could overestimate the AIF because of the metabolite activity. Without correcting for the metabolite activity, results from kinetic analysis based on the overestimated AIF would be erroneous.

The metabolites can be separated from the parent tracer using chromatographic technique like thin layer chromatography (TLC), high performance liquid chromatography (HPLC) (2,3) or micellar chromatography (4). Before analysis by liquid chromatography techniques, the samples would require pre-treatment like solid phase extraction or protein precipitation to prevent clogging of the columns or to prevent protein binding (1,4). These pre-analysis preparations require a high amount of manual manipulation, which may pose a safety hazard from routine use (5). A faster method that does not require sample preparation and hence less radio-sample exposure is column switching HPLC. However, the build-up of pressure in the column limits the number of samples to be injected into the column (6). HPLC is widely used in analytical chemistry and pharmaceutical industry and research to determine the purity of samples. It has high resolution between metabolites and parent tracer with high sensitivity in radioactivity detection due to the use of a scintillation detector coupled with a photo-multiplier tube (7). However, as a serial analyzer, HPLC can only analyze one sample at a time which can take up to 20 min for each sample. These instruments rely on finely tuned pumps, sensitive detectors, and various separation media. This results in high initial purchasing and upkeep costs. Finally, HPLC separation is susceptible to impurities in the solvent mobile phases (1).

An economical alternative to HPLC is TLC which is a simpler version of HPLC. It is not susceptible to impurities and multiple samples can be analyzed at the same time. The major drawbacks are that TLC suffers from poorer analyte resolution and requires a very sensitive detector to detect analytes at low concentration on the TLC plate. Different techniques have been developed in the past for radio-TLC. Earlier techniques include the zonal

analysis (8) and autoradiography technique where the TLC plate is directly exposed to x-ray film (9). Later, radio-scanners were developed that measured radioactivity at 1 – 2 mm steps. These techniques have poor analyte resolution (albeit from the intrinsic TLC characteristics), low sensitivity (MBq/mL range), and usually require long exposure time from hours to months for low activity samples and are prone to error (7,9). Therefore, our objective was to explore a different detection system with improved sensitivity and time efficiency for radio-TLC. Furthermore, the effect of radio-metabolites in the blood plasma on the accuracy of parameters estimated by kinetic analysis of dynamic PET was assessed using simulation study.

## 2. Methods

### 2.1. Beaver autoradiography system

Beaver autoradiography (ai4r, France) is a multimodality real time digital autoradiography system that can image beta and alpha particles (10). The detector is based on the principle of micro pattern gaseous detector (MPGD) using 90% Ne and 10% CO<sub>2</sub> gas supply which is commercially available in compact gas cylinders . The one we used was designed for imaging large samples with high spatial resolution of 50µm and sensitivity of  $5 \times 10^{-4}$  cpm.mm<sup>-2</sup> (11). It requires a continuous of supply of the gas mixture at a pressure of 1.1 bar. The detector is comprised of two drift zones alternating with two amplification zones separated by nickel micromeshes (Figure 1). The special feature of the drift zone is the low electric field (1kV/cm) that guides the electrons from the site of ionization by beta particles from radionuclide decay into the amplification zone (12). Electrons are multiplied by avalanche effect in the amplification zone due to kinetic energy imparted by the high electric field. The amplification zones are shallow in depth (50µm) to limit the spread of electron avalanche (cloud) and hence improve spatial resolution (13). The TLC plate is used as the cathode of the detector and serves as the back end of the first drift zone to prevent back flux of electrons. The electron cloud exiting the second amplification zone is captured by the pixelated reading anode.

### 2.2. Animal protocol

All experimental procedures were approved by and performed in accordance with guidelines of the Animal Ethics Committee of the University of Western Ontario.. Five farm pigs were procured from a farm nearby and two athymic Rowett Nude (RNU) rats were purchased from Charles River (Saint Constant, Quebec, Canada). The C57BL/10J mouse used in optimization of [<sup>18</sup>F]FEPPA mobile phase was purchased from Jackson Laboratory (Maine, USA). The animals were under no dietary restriction with free food access before each experiment. Pigs were first

anesthetized with Telazole intramuscular injection (1 mL/kg) while rats and mouse by masking with 5% isoflurane, and maintained using isoflurane at 2-3% balanced oxygen and medical air. Pigs ( $33.7 \pm 9.33$  kg) were used for [ $^{18}\text{F}$ ]FEPPA ( $21.9 \pm 6.34$  MBq/kg) analysis. RNU rats ( $309.75 \pm 29.64$  g) were used for [ $^{18}\text{F}$ ]FAZA ( $49.54 \pm 9.39$  MBq/kg) analysis. The tracers were manufactured at the cyclotron/radiochemistry facility of our institution following published procedures (14,15). Blood samples were drawn at 8 time points post tracer injection (p.i.) – 5, 10, 15, 20, 30, 40, 50 and 60 min. Each rat underwent two blood draws, two weeks apart, to make up a total of 4 sets of rat blood samples. For rats, blood (0.2 mL) was drawn for each sample from a tail vein using heparinized syringe into plasma separator tube. Due to the larger total blood volume of pigs, 2mL of blood was drawn for each sample from a cephalic vein into EDTA coated tubes.

### **2.3. Blood preparation for metabolite analysis**

The blood samples were immediately placed on ice to prevent further catabolism. Within 1-2 min after the last sample was taken, all samples were centrifuged at 1,000G in Sero-fuge II centrifuge (Clay-Adams Company, Inc.) for 5 minutes. The supernatant plasma was aspirated for radio-metabolite analysis.

### **2.4. Thin Layer Chromatography (TLC) preparation**

Silica coated TLC plates with  $F_{254}$  fluorescent indicator were purchased from MilliporeSigma. Each plate was scored to a height of 9 cm to fit the 13x9 cm holder of the Beaver TLC detector. Blood plasma (2  $\mu\text{L}$ ) from each blood sample was spotted 1 cm from the bottom of the plate with a micropipette. For optimal use of each imaging session with the TLC detector, two 5 cm wide plates were used. Five samples including one parent tracer reference (0.11 – 0.30 MBq in 3 – 5 mL of isotonic saline) can be spotted on each plate. The plate was air dried after spotting then immersed into the mobile phase in a beaker, making sure the solution was less than 5 mm high. The beaker was then covered with parafilm wax paper. The TLC plate developed for approximately 15 minutes until the solvent (mobile phase) front was roughly 1cm from the top of the plate. The plate was then removed, air dried, and imaged with the autoradiographic detector for 4 h.

### **2.5. Optimization of the mobile phase**

Using different volume fractions of ethyl acetate, methanol, and hexane, the mobile phase was optimized for each tracer. The solution that allowed the least polar analyte to migrate furthest away from the spotting baseline

as well as giving a good separation of the metabolites from the unmodified tracer in the autoradiography image was selected as optimized solution. Due to poor analyte resolution with TLC, the plasma metabolites did not appear as discrete spots. [<sup>18</sup>F]FEPPA and [<sup>18</sup>F]FAZA were optimized with blood from a mouse and a pig, drawn at 90 min and 60 min p.i. respectively. In this study, with the optimized mobile phase (solvent), the parent tracer was always closest to the solvent front after the TLC plate was developed.

## 2.6. Image analysis

Autoradiography images were analyzed with Analyze 12.0 (Analyze Software System). Line profiles were generated by summing the detected counts in a 7 mm segment centered on the sample “track” at 10 mm intervals.

For line profiles where the adjacent metabolite peak overlapped with the parent tracer peak, the area underneath the latter was estimated with a custom developed program using MATLAB (The MathWorks, Inc.). These line profiles were fitted with two Gaussian functions. The parent tracer peak area was determined as the area of the fitted Gaussian between the limits of  $\mu \pm 1.96 \sigma$ , where  $\mu$  is the mean and  $\sigma$  is the standard deviation. For spots where the adjacent metabolite peak did not overlap with the parent tracer peak, the latter was fitted with a Gaussian function and the parent tracer peak area was similarly determined as for the case of overlap.

The fraction of the parent tracer was calculated using the formula:

$$fraction = \frac{Area\ under\ native\ tracer}{Total\ area\ under\ line\ profile}$$

Each estimated parent tracer fraction for different times p.i. was compared to published literature values for validation.

## 2.7. Effect of radio-metabolites on kinetic parameter estimation

The kinetic parameters associated with the tracer uptake are obtained by deconvolving the AIF of the parent tracer from the measured tissue concentration curve or tissue time activity curve (TAC). A simulation study was performed to observe the effect of blood plasma radio-metabolites in the estimation of kinetic parameters. For simulating the tissue TAC, our in-house flow modified two compartment (F2TC) model (16) that models the bi-directional

permeation of the endothelial barrier during the transit time of the tracer through blood vessels, was utilized. The flow scaled impulse residue function (IRF<sub>F</sub>(t)) for the model is expressed as:

$$IRF_F(t) = \begin{cases} F & 0 \leq t < W \\ Ge^{-\alpha(t-W)} + He^{-\beta(t-W)} & t \geq W \end{cases}$$

where F is the blood flow, W is the mean transit time through blood vessels and G, H,  $\alpha$  and  $\beta$  are the fitting parameters obtained by iteratively fitting tissue TAC with non-linear 'interior point' optimization technique. The model's explicit parameters can be calculated from the fitting parameters as follows:

$$K_1 = G + H; \quad k_2 = \frac{G\alpha + H\beta}{G + H}$$

$$k_3 = \frac{GH(\alpha - \beta)^2}{(G + H)(G\alpha + H\beta)}; \quad k_4 = \frac{(G + H)\alpha\beta}{(G\alpha + H\beta)} = \frac{\alpha\beta}{k_2}$$

The explicit parameters are the influx ( $K_1$ ) and efflux ( $k_2$ ) rate constant of tracer through the blood tissue barrier and  $k_3$  and  $k_4$  are the binding and disassociation rate constant of the parent tracer to and from the target respectively.

The measured AIF with metabolite contamination, AIF<sub>m</sub> was simulated using Feng's model (17,18):

$$AIF_m(t) = [A_1(t - t_0)^\alpha - A_2 - A_3]e^{-\lambda_1(t-t_0)} + A_2e^{-\lambda_2(t-t_0)} + A_3e^{-\lambda_3(t-t_0)}$$

where  $A_1 = 800$ ,  $\alpha = 1.0$ ,  $A_2 = 20$ ,  $A_3 = 20$ ,  $\lambda_1 = 4 \text{ min}^{-1}$ ,  $\lambda_2 = 0.015 \text{ min}^{-1}$ ,  $\lambda_3 = 0.15 \text{ min}^{-1}$ ,  $t_0 = 0.15 \text{ min}$

AIF<sub>m</sub> was simulated at 0.5 s and corrected for radio-metabolite by multiplying with the fraction of parent [<sup>18</sup>F]FEPPA measured in §3.4:

$$AIF_c = AIF_m * \text{fraction}$$

The corrected AIF<sub>c</sub> was used to simulated tissue TAC at 0.5 s with ten sets of parameters (Table 1) from patients with high grade glioma (19). All the curves were frame averaged according to the following frame schedule: 10 @ 10 s, 5 @ 20 s, 4 @ 40 s, 4 @ 60 s, 11 @ 180 s and 1 @ 120 s (total 45 min). The two sets of kinetic parameters estimated by deconvolving AIF<sub>m</sub> and AIF<sub>c</sub> from simulated tissue TACs were compared. The difference of the parameters

estimated with and without metabolite correction was tested for statistical significance using non-parametric test – either Wilcoxon signed rank or sign test depending on whether the distribution of the differences was symmetric or non-symmetric, respectively.  $P < 0.05$  was declared significant with Bonferroni correction for multiple comparison with 8 parameters ( $K_1, k_i$  ( $i = 2,3,4$ ),  $V_p, DV, W, K_i$ ).

**Table 1** Ten parameter sets used for simulating the effect of radio-metabolite correction in blood plasma

SET#	$K_1$ (mL·min <sup>-1</sup> ·g <sup>-1</sup> )	$k_2$ (min <sup>-1</sup> )	$k_3$ (min <sup>-1</sup> )	$k_4$ (min <sup>-1</sup> )	$F$ (mL·min <sup>-1</sup> ·g <sup>-1</sup> )	$W$ (s)	$V_p$ (mL·g <sup>-1</sup> )	$DV$ (mL·g <sup>-1</sup> )
1	0.0930	0.5920	0.1840	0.0410	0.37	7	0.043	0.8621
2	0.1370	0.3310	0.2300	0.0700	0.27	7	0.032	1.7738
3	0.0740	0.3440	0.1520	0.0370	0.10	10	0.016	1.0988
4	0.0720	0.4580	0.2880	0.0770	0.29	10	0.048	0.7452
5	0.2220	0.4720	0.1900	0.0870	0.44	5	0.037	1.4975
6	0.1940	0.3280	0.2830	0.1720	0.26	15	0.065	1.5646
7	0.0960	1.0000	0.3060	0.0670	0.38	8	0.051	0.5344
8	0.1010	0.5180	0.3510	0.0750	0.20	10	0.034	1.1075
9	0.4790	1.0000	0.2210	0.1370	0.64	10	0.106	1.2517
10	0.2180	0.4980	0.4480	0.0840	0.87	15	0.218	2.7724

### 3. Results

#### 3.1. Optimization of the mobile phase

The separation of radio-metabolites in blood plasma with different mixtures of methanol, hexane and ethyl acetate for both tracers is shown in Figure 2. The optimized mobile phase for [<sup>18</sup>F]FEPPA and [<sup>18</sup>F]FAZA were 8% methanol and 10% hexane in ethyl acetate (v/v; fourth solution) and 7% methanol in ethyl acetate (v/v; third solution) respectively.

#### 3.2. Autoradiography

Figure 3 shows the autoradiographic images obtained from TLC plasma metabolite analysis of [<sup>18</sup>F]FAZA (rat) or [<sup>18</sup>F]FEPPA (pig), respectively. Each image showed two TLC plates with the parent tracer in normal saline as reference on each, as well as plasma obtained at different times p.i.

Since the reference parent tracer spot moved the furthest from the spotting baseline, it was the least polar analyte. The spots with similar retention factors ( $R_f$ ) to the reference spots were the fractions of the parent tracer in plasma at different times p.i. For [ $^{18}\text{F}$ ]FAZA on the left, the reference spots'  $R_f$  was  $0.66 \pm 0.01$ . Most of the activity was from the parent tracer while that at the spotting line could be from the more polar radio-metabolites. Significant conversion of tracer to radio-metabolite was observed from 50 min p.i. For [ $^{18}\text{F}$ ]FEPPA on the right, the reference spots'  $R_f$  was  $0.54 \pm 0$ . Radio-metabolites were observed as early as 5 min p.i. as indicated by activity directly below the reference  $R_f$  as well as activity along the spotting line. At 1 h p.i., the parent tracer spot almost disappeared as there was almost complete conversion into metabolites observed as activity all along the track.

### 3.3. Line profile

Figure 4 shows the line profiles of selected [ $^{18}\text{F}$ ]FEPPA spots – reference, 5 min and 1 h p.i. – corresponding to the right image of Figure 3. For the reference, a well-defined peak was observed due to high signal to noise ratio. At 5 min p.i., three prominent peaks were discernible. The peak on the furthest right was the parent [ $^{18}\text{F}$ ]FEPPA, the peak for the least polar radio-metabolite was close to the parent tracer. The most polar radio-metabolite was located close to the spotting baseline. At 1 h p.i., the parent [ $^{18}\text{F}$ ]FEPPA peak was not identifiable. A new peak corresponding to radio-metabolites of intermediate polarity was observed and the amount of the most polar radio-metabolite increased, as indicated by the area. Therefore, the parent [ $^{18}\text{F}$ ]FEPPA was almost completely metabolized to radio-metabolites at 1 h p.i.

**Table 2** Coefficient of variation of parent tracer fraction for [ $^{18}\text{F}$ ]FEPPA and [ $^{18}\text{F}$ ]FAZA

	5 min	10 min	15 min	20 min	30 min	40 min	50 min	60 min
[ $^{18}\text{F}$ ]FEPPA	0.07	0.13	0.17	0.17	0.24	0.32	0.26	0.43
[ $^{18}\text{F}$ ]FAZA	0.02	0.03	0.03	0.04	0.01	0.03	0.12	0.25

### 3.4. Fraction of parent tracer versus post-injection time

Figure 5 shows the fraction of parent [ $^{18}\text{F}$ ]FAZA and [ $^{18}\text{F}$ ]FEPPA in blood at different times post-injection. For [ $^{18}\text{F}$ ]FAZA, the fraction of parent tracer remained relatively constant at 91% until 40 min p.i. The fraction then decreased to 62% and 40% at 50 and 60 min p.i., respectively. On the other hand, close to 50% of activity in blood

was from [ $^{18}\text{F}$ ]FEPPA metabolites as early as 5 min p.i. and the parent tracer fraction decreased to 19% at 1 hour p.i.

Table 2 shows the coefficient of variation (CoV) of the parent tracer fraction arising from inter-subject variability.

For [ $^{18}\text{F}$ ]FEPPA, CoV ranged from 0.07 to 0.43 while [ $^{18}\text{F}$ ]FAZA from 0.01 to 0.25.

**Table 3** Median differences in parameters estimated from simulation study

Parameter	$K_1$ ( $\text{mL}\cdot\text{min}^{-1}\cdot\text{g}^{-1}$ )	$k_2$ ( $\text{min}^{-1}$ )	$k_3$ ( $\text{min}^{-1}$ )	$k_4$ ( $\text{min}^{-1}$ )	$V_p$ ( $\text{mL}\cdot\text{g}^{-1}$ )	DV ( $\text{mL}\cdot\text{g}^{-1}$ )	W (min)
Median difference	0.003	-0.124	0.111	-0.052	0.004	0.806	0.021
P	0.75	0.004	0.005	0.004	0.013	0.004	0.083
* Bias (%)	198.3	-32.7	115.4	-390.3	109.2	81.2	181.0

Median differences between parameters in table 1 estimated using AIF with and without metabolite correction. P value is estimated by non-parametric paired test. \*Although the differences in the estimated parameters were not normally distributed, the percentage bias was used to approximate the expected error

### 3.5. Simulation study

Due to conversion of parent tracer to radio-metabolite, metabolite correction lowered the AIF as p.i. time increased (Figure 6(a)). When  $\text{AIF}_c$  was deconvolved from the tissue TACs, the parameters estimated were statistically different from those estimated by deconvolving  $\text{AIF}_m$ ; errors greater than 32% were observed for all parameters (Table 3).

## 4. Discussion

In this study, we established an alternate method to HPLC to determine the fraction of radio-labeled parent tracer at different times p.i. based on inexpensive TLC and a sensitive beta detector. Fraction of unmetabolized [ $^{18}\text{F}$ ]FAZA and [ $^{18}\text{F}$ ]FEPPA in normal healthy rats and pigs (respectively) p.i. were measured and compared to literature values, if available. There were large variations in the rate of metabolite production with the same tracer (either [ $^{18}\text{F}$ ]FAZA or [ $^{18}\text{F}$ ]FEPPA) and between the two tracers in the same and different animals. CoV of parent tracer fraction in blood could be as high as 43%. In addition, simulation study investigating the effect of radio-metabolite correction in measured arterial curve suggested that large error (30 – 400%) can result in the estimation of kinetic parameters if correction was not incorporated.

The acquired autoradiography images showed clear distinction between radio-metabolites and the parent tracer. The large signal difference between reference and plasma sample was due to 6.7 times difference in the activity between the two. Reference [<sup>18</sup>F]FEPPA (parent tracer in normal saline) was spotted with activity of  $126 \pm 17$  Bq in 2  $\mu$ L while plasma samples from pigs were lower in activity – at 5 min p.i. the activity was approximately 17 Bq in 2  $\mu$ L. For our metabolite studies, either  $15.2 \pm 1.8$  MBq (41– 59MBq/kg) or 427 – 1216 MBq (13 – 27 MBq/kg) was administered for the rat ([<sup>18</sup>F]FAZA) and pig ([<sup>18</sup>F]FEPPA), respectively at the time of injection. These were lower than other published metabolite studies in mice where doses ranging from 20 – 30 MBq (1 GBq/kg) (20) to as high as 68 MBq (3.4 GBq/kg) (21) of tracer were administered due to the lower sensitivity of the radiation detector used. In our studies, even with >77 times less dose (normalized to body weight to account for the body mass of different species), peaks corresponding to the parent tracer could be distinguished from radio-metabolites. In the few cases where radio-metabolites overlapped with the parent tracer because of similar polarity and hence strength of adhesion to the silica media, the parent tracer peak could be adequately resolved by the curve fitting procedure discussed in §2.6. Taken the above results together, our method of combining TLC and the Beaver proprietary beta particle detector has the analyte resolution and sensitivity for blood metabolite determination for both [<sup>18</sup>F]FAZA and [<sup>18</sup>F]FEPPA in individual large (pig) or small (rodents) animals. Nevertheless, by comparing the [<sup>18</sup>F]FEPPA dose used in our pig studies (13–27 MBq/kg) to the published patient dose (2.5 – 6.2 MBq/kg (22–25)) the sensitivity of the detector has to be increased by at least 5 times for the method to be used for blood metabolite determination in individual patients.

From the [<sup>18</sup>F]FEPPA results (Table 2), inter-subject variation was observed with more pronounced variability at later time points p.i in agreement with other studies (22,26,27) showing inter-subject variabilities. This supports our view that the current practice of using a population average in normal subjects to correct for metabolite contamination (26) is not optimal for kinetic analysis and there is a need to determine blood metabolite in individual studies. Furthermore, simulation study (as shown in Supplement) validated the requirement of individualized metabolite correction. With our method, multiple samples can be analyzed together within one imaging session, the exact number of samples depends on the detector size. Currently, we can analyze 8 samples but with a larger

detector size, the number of samples can be increased to 12 or more making it feasible for individualized radio-metabolite analysis.

The effect of not correctly accounting for blood radio-metabolite was investigated with computer simulation using a previously published kinetics model (16). For all parameter sets listed in Table 1, the fitting to the simulated tissue time activity curve (TAC) failed when radio-metabolite contamination was not corrected for in the arterial TAC. This failure led to large errors (30 – 400%) in parameter estimation and possible misinterpretation of the tracer pharmacokinetics. For instance, distribution volume of [ $^{18}\text{F}$ ]FAZA is related to the amount and activity of nitroreductase present in hypoxic tissue (28) while that of [ $^{18}\text{F}$ ]FEPPA is related to density and activity of translocator protein (TSPO) found on the outer mitochondrial membrane (29), particularly within activated immune cells (30). Additional simulations were performed to investigate how intersubject variability in parent tracer fractions over time would affect the accuracy of the estimated kinetic parameters. As indicated in Figure S2, the percentage bias of the same parameters as in Table 3 -  $K_1$ ,  $k_2$ ,  $k_3$ ,  $k_4$ ,  $V_p$ ,  $DV$ , and  $W$ , differs widely without and with correction for the different parent tracer fractions. Therefore, individualization of metabolite correction is necessary for accurate measurement of kinetic parameters in dynamic PET. In this study, the F2TC model (16) was used since it incorporates the bi-directional permeability of the blood-tissue barrier during the vascular transit time. The failure to properly model the transit time could introduce additional biases in parameter estimation.

Our measured fractions of parent [ $^{18}\text{F}$ ]FEPPA in blood over time p.i. agreed well with those obtained by Rusjan et al. (22). On the other hand, measured fractions of parent [ $^{18}\text{F}$ ]FAZA over time p.i. were not found in literature. Studies of [ $^{18}\text{F}$ ]FAZA by Verwer et al. showed that only 10% of the activity in blood was from metabolites at 70 min p.i. (24) with the use of solid phase extraction and HPLC. Our study showed that significant metabolite fraction (~ 10%) in blood started at 40 min and increased to 60% at 60 min p.i. Jans et al (20) also used TLC to estimate the metabolite fraction in blood and no metabolite was observed. However, there were two mitigating factors with their experiments that could explain the difference in the measured metabolite fraction in blood. First, it was not known whether the mobile phase used was optimized for the tracer; second, the detector used may not be as sensitive as our one.

The time required for blood metabolite analysis using our method starting with the collected blood samples (excluding the image processing time) comprised of: 5 min of centrifugation, 5 min for spotting samples on and drying the TLC plate, and 15 minutes of TLC plate development for a total of 25 – 30 minutes. Technically, the solvent front is required to move beyond the furthest point the samples or the parent tracer moved during development. In our experiments, the parent tracer (either [<sup>18</sup>F]FAZA or [<sup>18</sup>F]FEPPA) which moved the furthest, moved approximately 4.5 cm while the solvent front moved over 7 cm. Therefore, the development time can be shortened to 10 min. The autoradiograph image was acquired over 4 h in this study. However, one-hour acquisition was tested, the acquired image showed good image quality (signal-to-noise ratio) as shown in the supplementary Figure S3. Similar to HPLC with automated injector, once the blood samples are prepared, all the samples can be analyzed/imaged within an hour without an operator.

Other comparative similarities and differences between our method and HPLC are listed in Table 4.

**Table 4** Differences and similarities between radio-HPLC and TLC-autoradiography

Properties	Radio-HPLC	TLC – autoradiography
Volume of plasma required	1-2000 $\mu$ L(31)	2 $\mu$ L
Mobile Phase Optimization	Required	Required
Analyte Resolution	High	Low – overlap of analyte peaks can be resolved by Gaussian fitting
Analyte Identification*	Yes	No
Sample Analysis Mode	Serial	Multiplex
Operation	<ul style="list-style-type: none"> <li>• May require separate HPLC column for each tracer</li> <li>• HPLC column requires regular washing to prevent clogging and removal residual analytes from previous runs (1,32)</li> </ul>	<ul style="list-style-type: none"> <li>• Single use inexpensive TLC plate for each run</li> <li>• Single use TLC – no maintenance is required</li> </ul>
Tissue Section Autogradiography	No	Yes

\* The chemical identity of the radio-metabolites is not required for metabolite fraction correction.

Taking all the above comparative advantages and disadvantages of our method and HPLC into consideration, we conclude that our method could be more suited for individualized metabolite measurement in blood than HPLC.

Note that independent of whether the AIF is measured with timed arterial blood sample or is image derived by measuring the activity in an arterial region in dynamic PET images, metabolite correction is required.

As shown in autoradiography images, the resolution is poor which could be improved by altering the pH of the mobile phase. Since the silica stationary phase tends to be acidic, adding trialkyl amines can improve the resolution of basic moieties present in the analytes. Similarly, addition of a small percentage of acetic or formic acid can reduce so called streaking of acidic moieties. Additionally, alternative stationary phases such as alumina or cellulose could be used to improve resolution of individual metabolites. Ultimately, as percentage of parent fraction is the main outcome measurement from TLC analysis, these optimizations may prove unproductive (33). Furthermore, the signal to background ratio of the autoradiographic image can be improved by injecting higher amount of radioactive tracer.

There are several limitations with our study. The measured blood metabolite fraction was not validated against the reference HPLC method. However, our [ $^{18}\text{F}$ ]FEPPA results agreed with literature values measured with reverse phase HPLC (Figure 6(b)). The number of blood samples used for each tracer was small. Even with this small number of animals, the inter-subject variability in metabolite fraction was prominent (Table 2) suggesting that this result could be the true *in vivo* situation and the importance to measure metabolite fraction for each individual subject. We investigated only two tracers, [ $^{18}\text{F}$ ]FEPPA and [ $^{18}\text{F}$ ]FAZA, as examples. Since analyte separation of TLC depends on the polarity of the tracer and its metabolites, for other tracers the mobile phase will have to be optimized. We have tested our method only with the  $^{18}\text{F}$  radionuclide. Since other common PET radionuclides including  $^{11}\text{C}$ ,  $^{13}\text{N}$ ,  $^{68}\text{Ga}$  and  $^{89}\text{Zr}$  emit  $\beta^-$  particles in their decay, our method would also work except, like the mobile phase, the limit of radioactivity detection must be determined for each radionuclide separately.

## 5. Conclusion

We were able to measure the fraction of parent radiolabeled tracer in blood after it was injected into the body using TLC and the Beaver autoradiography system. This fraction is required to correct the AIF obtained by measuring the activity in timed arterial blood samples or in arterial region in dynamic PET images. Without this correction, the AIF will be overestimated leading to errors in the kinetic analysis of dynamic PET. Although we used

two specific tracers, [ $^{18}\text{F}$ ]FAZA and [ $^{18}\text{F}$ ]FEPPA, to develop the method, the system can be used for other tracers by optimizing the mobile phase for each of them. Due to its capability to analyze multiple (>8) blood samples at the same time with preparation time as short as 25 – 30 min, our method will enable individualize blood metabolite correction for kinetic analysis of dynamic PET.

## References

1. Pawelke B. Metabolite analysis in positron emission tomography studies: Examples from food sciences. *Amino Acids*. 2005;29(4 SPEC. ISS.):377–88.
2. Wang RF, Loc'h C, Mazière B. Determination of unchanged [<sup>18</sup>F]dopamine in human and nonhuman primate plasma during positron emission tomography studies: A new solid-phase extraction method comparable to radio-thin-layer chromatography analysis. *J Chromatogr B Biomed Appl*. 1997;693(2):265–70.
3. Ma Y, Kiesewetter DO, Lang L, Der M, Huang B, Carson RE, et al. Determination of [<sup>18</sup>F]FCWAY, [<sup>18</sup>F]FP-TZTP, and their metabolites in plasma using rapid and efficient liquid-liquid and solid phase extractions. *Nucl Med Biol*. 2003;30(3):233–40.
4. Nakao R, Halldin C. Improved radiometabolite analysis procedure for positron emission tomography (PET) radioligands using a monolithic column coupled with direct injection micellar/high submicellar liquid chromatography. *Talanta*. 2013;113:130–4.
5. Robards K, Haddad PR, Jackson PE. *Principles and Practice of Modern Chromatographic Methods*. Academic Press; 1994. 1–32 p.
6. Hilton J, Yokoi F, Dannals RF, Ravert HT, Szabo Z, Wong DF. Column-switching HPLC for the analysis of plasma in PET imaging studies. *Nucl Med Biol*. 2000;27(6):627–30.
7. Takei M, Kida T, Suzuki K. Sensitive measurement of positron emitters eluted from HPLC. *Appl Radiat Isot*. 2001;55(2):229–34.
8. Snyder F, Cress E. Application of thin-layer chromatographic zonal <sup>14</sup>C-Profile scans to the analysis of urinary constituents derived from lipids. *Clin Chem*. 1968;14(6):529–34.
9. Marx AM, Kronberg H, Neuhoff V. Determination of the specific radioactivity of amino acids by a combination of thin-layer chromatography and quantitative autoradiography. *J Chromatogr*. 1987;393(19):407–17.

10. Sardini P, Angileri A, Descostes M, Duval S, Oger T, Patrier P, et al. Quantitative autoradiography of alpha particle emission in geo-materials using the Beaver<sup>TM</sup> system. *Nucl Instruments Methods Phys Res Sect A Accel Spectrometers, Detect Assoc Equip.* 2016;833:15–22.
11. Ai4r. BeaQuant [Internet]. 2017 [cited 2020 Jan 31]. Available from: <http://www.ai4r.com/real-time-autoradiography/product/>
12. Titov M. Perspectives of Micro-Pattern Gaseous Detector Technologies for Future Physics Projects. 2013;1–14. Available from: <http://arxiv.org/abs/1308.3047>
13. Donnard J, Arlicot N, Berny R, Carduner H, Leray P, Morteau E, et al. Advancements of labelled radio-pharmaceutics imaging with the PIM-MPGD. *J Instrum.* 2009;4(11):1–9.
14. Wilson AA, Garcia A, Parkes J, McCormick P, Stephenson KA, Houle S, et al. Radiosynthesis and initial evaluation of [18F]-FEPPA for PET imaging of peripheral benzodiazepine receptors. *Nucl Med Biol.* 2008;35(3):305–14.
15. Hayashi K, Furutsuka K, Takei M, Muto M, Nakao R, Aki H, et al. High-yield automated synthesis of [18F]fluoroazomycin arabinoside ([18F]FAZA) for hypoxia-specific tumor imaging. *Appl Radiat Isot* [Internet]. 2011;69(7):1007–13. Available from: <http://dx.doi.org/10.1016/j.apradiso.2011.02.025>
16. Yang DM, Palma D, Louie A, Malthaner R, Fortin D, Rodrigues G, et al. Assessment of tumour response after stereotactic ablative radiation therapy for lung cancer: A prospective quantitative hybrid 18 F-fluorodeoxyglucose-positron emission tomography and CT perfusion study. *J Med Imaging Radiat Oncol.* 2019;63(1):94–101.
17. Feng D, Huang S-C, Wang X. Models for computer simulation studies of input functions for tracer kinetic modeling with positron emission tomography. *Int J Biomed Comput.* 1993;32(2):95–110.
18. Ben Bouallègue F, Vauchot F, Mariano-Goulart D. Comparative assessment of linear least-squares, nonlinear least-squares, and Patlak graphical method for regional and local quantitative tracer kinetic modeling in cerebral dynamic 18 F-FDG PET. *Med Phys.* 2019;46(3):1260–71.

19. Debus C, Afshar-Oromieh A, Floca R, Ingrisch M, Knoll M, Debus J, et al. Feasibility and robustness of dynamic  $^{18}\text{F}$ -FET PET based tracer kinetic models applied to patients with recurrent high-grade glioma prior to carbon ion irradiation. *Sci Rep.* 2018;8(1):1–17.
20. Jans HS, Yang XH, Brocks DR, Kumar P, Wuest M, Wiebe LI. Positron emission tomography (PET) and pharmacokinetics: Classical blood sampling versus image-derived analysis of [ $^{18}\text{F}$ ]FAZA and [ $^{18}\text{F}$ ]FDG in a murine tumor bearing model. *J Pharm Pharm Sci.* 2018;21(1S):32s-47s.
21. Vignal N, Cisternino S, Rizzo-Padoin N, San C, Hontonnou F, Gelé T, et al. [ $^{18}\text{F}$ ]FEPPA a TSPO radioligand: Optimized radiosynthesis and evaluation as a PET radiotracer for brain inflammation in a peripheral LPS-injected mouse model. *Molecules.* 2018;23(6).
22. Rusjan PM, Wilson AA, Bloomfield PM, Vitcu I, Meyer JH, Houle S, et al. Quantitation of translocator protein binding in human brain with the novel radioligand  $^{18}\text{F}$ -FEPPA and positron emission tomography. *J Cereb Blood Flow Metab.* 2011;31(8):1807–16.
23. Mizrahi R, Rusjan PM, Vitcu I, Ng A, Wilson AA, Houle S, et al. Whole Body Biodistribution and Radiation Dosimetry in Humans of a New PET Ligand, [ $^{18}\text{F}$ ]FEPPA, to Image Translocator Protein (18 kDa). *Mol Imaging Biol.* 2013;15(3):353–9.
24. Verwer EE, van Velden FHP, Bahce I, Yaqub M, Schuit RC, Windhorst AD, et al. Pharmacokinetic analysis of [ $^{18}\text{F}$ ]FAZA in non-small cell lung cancer patients. *Eur J Nucl Med Mol Imaging* [Internet]. 2013;40(10):1523–31. Available from: <http://link.springer.com/10.1007/s00259-013-2462-3>
25. Savi A, Incerti E, Fallanca F, BettinarDi V, Rossetti F, Monterisi C, et al. First evaluation of PET-based human bioDistribution and dosimetry of  $^{18}\text{F}$ -FAZA, a tracer for imaging tumor hypoxia. *J Nucl Med.* 2017;58(8):1224–9.
26. Hinz R, Bhagwagar Z, Cowen PJ, Cunningham VJ, Grasby PM. Validation of a tracer kinetic model for the quantification of 5-HT 2A receptors in human brain with [ $^{11}\text{C}$ ]MDL 100,907. *J Cereb Blood Flow Metab.* 2007;27(1):161–72.

27. Henriksen G, Spilker M, Sprenger T, Hauser A, Platzer S, Boecker H, et al. Gender dependent rate of metabolism of the opioid receptor-PET ligand [18F]fluoroethyldiprenorphine. *Nuklearmedizin*. 2006;45(5):197–200.
28. Nunn A, Linder K, Strauss HW. Nitroimidazoles and imaging hypoxia. *Eur J Nucl Med*. 1995;22(3):265–80.
29. Anholt R, Pedersen P, De Souza E, Snyder S. The peripheral-type benzodiazepine receptor: localization to the mitochondrial outer membrane. *J Biol Chem*. 1986;261(2):576–83.
30. Veiga S, Carrero P, Perna O, Azcotta I, Garcia-Segura L. Translocator protein (18kDa) is involved in the regulation of reactive gliosis. *Glia* [Internet]. 2007;55:1425–36. Available from: <http://www.unscn.org/en/home/>
31. Silicycle. Ideal injection volume vs column dimension [Internet]. 2019 [cited 2020 May 5]. Available from: <https://www.silicycle.com/ca/faq/hplc/ideal-injection-volume-vs-column-dimension>
32. Wilson ID. Thin-layer chromatography: A neglected technique. *Ther Drug Monit*. 1996;18(4):484–92.
33. Touchstone J. *Practice of thin layer chromatography*. 3rd ed. Wiley; 1992.

#### **List of abbreviations**

AIF – Arterial input function

CoV – Coefficient of variation

DV – Distribution Volume

F – Blood flow

F2TC – Flow modified two compartment

HPLC – High performance liquid chromatography

IRF – Impulse residue function

$K_1$  – Influx rate constant

$k_2$  – Efflux rate constant

$k_3$  – Binding rate constant

$k_4$  – Disassociation rate constant

$K_i$  – Net influx rate

MPGD – Micro pattern gaseous detector

p.i. – Post injection

PET – Positron emission tomography

$R_f$  – retention factor

SPE – Solid –phase extraction

TAC – Time activity curve

TLC – Thin layer chromatography

$V_p$  – Blood Volume

$W$  – Mean transit time

## **Declarations**

**Ethics Approval:** All animal studies were performed in accordance with guidelines from the Animal Ethics Committee of the University of Western Ontario, Canada.

**Consent for publication:** Not applicable

**Availability of data and material:** The datasets used and/or analyzed during this study are available from the corresponding author on reasonable request.

**Competing interests:** The authors declare that they have no competing interests

**Funding:** This work was funded by a Quantitative Imaging Network grant from the Canadian Institutes for Health Research and National Institutes of Health (1 UO1 CA190256-01).

**Author's contribution:** FL and T-Y L were involved in the design of the experiment in consultation with JWH. LD, JH and LM helped with the animal experiments. LY synthesized the radiotracers. FL performed the blood analysis, designed the simulation study, analyzed and interpreted the results, and wrote the manuscript with the assistance of T-Y L and JWH.

#### **Acknowledgements:**

The authors thank Dr. Jerome Donnard and Remy Sence of ai4r (Nantes, France) for helpful discussions. This work was supported in part by Lawson Health Research Institute and Robarts Research Institute

#### **FIGURE LEGENDS**

##### **Fig. 1 Schematic of Beaver Autoradiography**

Working principle of Beaver MPGD for  $\beta^-$  particles. (Adapted from *J Instrum.* 2009;4:1-9 (11))

##### **Fig. 2 Autoradiographic image of mobile phase optimization for [ $^{18}\text{F}$ ]FAZA and [ $^{18}\text{F}$ ]FEPPA**

Mobile phase optimization for (a) [ $^{18}\text{F}$ ]FAZA and (b) [ $^{18}\text{F}$ ]FEPPA in pig and mouse blood respectively at 90 min and 60 min (respectively) post injection, using different fractions of methanol (M), and hexane ([H in ethyl acetate \(EA\)](#)). With each tracer, five different mixtures were used. For [ $^{18}\text{F}$ ]FAZA only plasma samples were used while for [ $^{18}\text{F}$ ]FEPPA each plasma sample was paired with the native tracer in normal saline as the reference (R). The optimal mobile phase would spread the radio-metabolites along the entire lane and move the reference furthest from the spotting line. For [ $^{18}\text{F}$ ]FEPPA the fourth solution from the left comprised of 8% methanol, 10% hexane and 82% ethyl acetate was optimal while for [ $^{18}\text{F}$ ]FAZA, it was the third solution comprised of 7% methanol and 93% ethyl acetate.

##### **Fig. 3 Autoradiographic image of plasma samples**

Autoradiography image of plasma samples obtained from a rat injected with [ $^{18}\text{F}$ ]FAZA (left) and from a pig injected with [ $^{18}\text{F}$ ]FEPPA (right). 'Ref' is the reference spot on each TLC plate. The number above each line shows the time in min at which the blood sample was drawn post tracer injection. The direction of motion of the mobile phase (solvent) front from capillary action was from bottom to top. The radio-metabolites that did not move with mobile phase show up as faint 'spots' at the bottom along the spotting line.

**Fig. 4 Line profile of [<sup>18</sup>F]FEPPA**

Line profile of [<sup>18</sup>F]FEPPA reference, plasma from a pig obtained at 5 min and 1 h post tracer injection. The y-axis is detected counts and the x-axis is distance in mm. The corresponding autoradiography image is displayed above the profile. The direction of movement of the solvent front from capillary action was from left to right

**Fig. 5 Fraction of parent tracer for [<sup>18</sup>F]FAZA and [<sup>18</sup>F]FEPPA**

Native tracer fraction vs time post injection (p.i.) for (a) [<sup>18</sup>F]FAZA and (b) [<sup>18</sup>F]FEPPA. The dashed line in (b) was native tracer fraction from (18). The error bar corresponds to standard deviation for 5 pig blood samples ([<sup>18</sup>F]FEPPA) and 4 rat blood samples ([<sup>18</sup>F]FAZA)

**Fig. 6 Simulation curves for estimating accuracy of kinetic parameter due radio-metabolite correction**

Curves utilized for simulating the effect of radio-metabolite on kinetic parameter estimation in dynamic PET cases. (a) Arterial curve simulated with Feng's model for measured (not corrected, dashed line) and radio-metabolite corrected curve (solid line). (b) Tissue curve simulated with parameter set #6 (table 1, solid square) and fitted curves obtained with measured arterial curve (dashed line) and with radio-metabolite corrected arterial curve (solid line).

**SUPPLEMENTARY FIGURE LEGENDS****Figure S1. Different parent tracer fractions over time to simulate inter-subject variability**

Different parent tracer fraction over time curves were simulated from that measured for [<sup>18</sup>F]FEPPA (Figure 5(b)) by contracting and expanding the time axis by different scale factors.

**Figure S2. Median differences in kinetic parameters estimated without and with metabolite correction according to the parent tracer fractions shown in Figure S1.**

Parameter numbers 1-7 correspond to the list of kinetic parameters -  $K_1, k_2, k_3, k_4, V_p, DV,$  and  $W$

**Figure S3. Comparison of autography image of 1-hr vs 4-hr acquisition duration.**

Image of blood plasma obtained from a rat injected with [<sup>18</sup>F]FAZA. The SNR of image (a) acquire for 1 hour is acceptable with discernible spots for native tracer and radio-metabolites. (b) The same TLC image that is acquired

for four hours immediately after (a) was acquired. The bright spot is the reference 'ref' parent tracer in saline followed by blood samples drawn at 30, 40, 50 and 60 minute post injection.

## SUPPLEMENT

### Simulation study to evaluate the effect of different time metabolite activity in the blood plasma on kinetic parameter estimation

To demonstrate how different metabolite activities in blood plasma affects the accuracy of estimated kinetic parameters, different time parent tracer fraction curves arising from intersubject variability were simulated from the measured [<sup>18</sup>F]FEPPA fraction curve in Figure 5 (b) and simulation studies were repeated according to section 2.7.

**Method:** Different time parent tracer fraction representing intersubject variability was simulated by expansion and contraction of the time (x-axis) axis of the measured [<sup>18</sup>F]FEPPA fraction, as determined from section 3.4. The function describing the fraction of parent [<sup>18</sup>F]-FEPPA over time was estimated by fitting the fraction with a bi-exponential curve as shown below:

$$fraction(t) = Ae^{-\alpha t} + Be^{-\beta t}$$

According to the fit, the fraction was best described with A = 0.5769, B = 0.4442.  $\alpha = 0.2657$ ,  $\beta = 0.0140$ . The expansion and contraction of the curve was accomplished by multiplying the time variable with a scale factor, k:

$$t = kt'$$

$$fraction'(t) = Ae^{-\frac{\alpha t'}{k}} + Be^{-\frac{\beta t'}{k}}$$

Where  $k$  can either be  $< 1$  or  $> 1$  to represent contraction and expansion respectively and  $fraction'(t)$  is the modified parent tracer fraction. For each simulated  $fraction'(t)$ , the simulation was performed in a similar fashion to section 2.7.

**Result:** Figure S2 shows the [<sup>18</sup>F]FEPPA fraction with varying  $k$  values.  $k = 1$  corresponds to the measured [<sup>18</sup>F]FEPPA fraction shown in Figure 5(b) and it is also the average of the parent fraction of  $k = 0.8, 0.9, 1.1$  and  $1.2$ , indicating that it simulates the population average. As indicated by Figure A2, the percentage bias of the same parameters as in Table 3 -  $K_1, k_2, k_3, k_4, V_p, DV$ , and  $W$ , as estimated by AIF<sub>m</sub> and AIF<sub>c</sub>, differs widely among the different scale

factors,  $k$ . Therefore, as advocated in the Discussion, individualization of metabolite correction is necessary for accurate measurement of kinetic parameters in dynamic PET.

# Figures




Figure 1

Schematic of Beaver Autoradiography Working principle of Beaver MPGD for  $\beta$ - particles. (Adapted from J Instrum. 2009;4:1-9 (11))





Figure 2


Autoradiographic image of mobile phase optimization for [18F]FAZA and [18F]FEPPA Mobile phase optimization for (a) [18F]FAZA and (b) [18F]FEPPA in pig and mouse blood respectively at 90 min and 60 min (respectively) post injection, using different fractions of methanol (M), and hexane (H) in ethyl

acetate (EA). With each tracer, five different mixtures were used. For  $[^{18}\text{F}]\text{FAZA}$  only plasma samples were used while for  $[^{18}\text{F}]\text{FEPPA}$  each plasma sample was paired with the native tracer in normal saline as the reference (R). The optimal mobile phase would spread the radio-metabolites along the entire lane and move the reference furthest from the spotting line. For  $[^{18}\text{F}]\text{FEPPA}$  the fourth solution from the left comprised of 8% methanol, 10% hexane and 82% ethyl acetate was optimal while for  $[^{18}\text{F}]\text{FAZA}$ , it was the third solution comprised of 7% methanol and 93% ethyl acetate.




**Figure 3**

Autoradiographic image of plasma samples obtained from a rat injected with  $[^{18}\text{F}]\text{FAZA}$  (left) and from a pig injected with  $[^{18}\text{F}]\text{FEPPA}$  (right). 'Ref' is the reference spot on each TLC plate. The number above each line shows the time in min at which the blood sample was drawn post tracer injection. The direction of motion of the mobile phase (solvent) front from capillary action was from bottom to top. The radio-metabolites that did not move with mobile phase show up as faint 'spots' at the bottom along the spotting line.




**Figure 4**

Line profile of  $[^{18}\text{F}]$ FEPPA reference, plasma from a pig obtained at 5 min and 1 h post tracer injection. The y-axis is detected counts and the x-axis is distance in mm. The corresponding autoradiography image is displayed above the profile. The direction of movement of the solvent front from capillary action was from left to right



**Figure 5**

Fraction of parent tracer for  $[^{18}\text{F}]$ FAZA and  $[^{18}\text{F}]$ FEPPA Native tracer fraction vs time post injection (p.i.) for (a)  $[^{18}\text{F}]$ FAZA and (b)  $[^{18}\text{F}]$ FEPPA. The dashed line in (b) was native tracer fraction from (18). The error bar corresponds to standard deviation for 5 pig blood samples ( $[^{18}\text{F}]$ FEPPA) and 4 rat blood samples ( $[^{18}\text{F}]$ FAZA)



**Figure 6**

Simulation curves for estimating accuracy of kinetic parameter due to radio-metabolite correction. Curves utilized for simulating the effect of radio-metabolite on kinetic parameter estimation in dynamic PET cases. (a) Arterial curve simulated with Feng's model for measured (not corrected, dashed line) and radio-metabolite corrected curve (solid line). (b) Tissue curve simulated with parameter set #6 (table 1, solid square) and fitted curves obtained with measured arterial curve (dashed line) and with radio-metabolite corrected arterial curve (solid line).

## Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- [FigS2.JPG](#)
- [FigS3.tiff](#)
- [FigS1.JPG](#)